Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase

References

• Ullrich A, Coussens L, Hayflick JS et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418–425 (1984).
   PubMed Web of Science ®Google Scholar
• ••Identified epithelial growth factor receptor(EGFR) as a homolog of the transforming oncogene v-erbB.
   Google Scholar
• Fan QW, Zhang C, Shokat KM, Weiss WA. Chemical genetic blockade of transformation reveals dependence on aberrant oncogenic signaling. CUI7: Biol. 12, 1386–1394 (2002).
   Google Scholar
• Arteaga C. Epidermal growth factor receptor in human tumors: more than just expression? Oncologist 7(S14), 31–39 (2002).
   Google Scholar
• Goel S, Mani S, Perez-Soler R. Tyrosine kinase inhibitors: a clinical perspective. Curr Oncol Rep. 4(1), 47–55 (2002).
   Google Scholar
• Riese DJ, Stern DE Specificity within the EGF family/ErbB receptor family signaling network. BioEssays 20(1), 41–48 (1998).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the erbB signalling network. Nat. Rev Mal Celi. Biol. 2, 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the complex ligand-receptor interaction and layered signaling network.
   Google Scholar
• Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 82(2-3), 207–218 (1999).
   Google Scholar
• Pollack V, Savage D, Baker DA et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effect in athymic mice. J. Pharmacol Exp. Ther. 291, 739–748 (1999).
   Google Scholar
• Umekita Y, Ohi Y, Sagara Y et al Co-expression of epidermal growth factor receptor and transforming growth factor-a predicts worse prognosis in breast cancer patients. Int.j Cancer89, 484–487 (2000).
   PubMed Web of Science ®Google Scholar
• Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. 71-encls Mal Med. 8(1), 17–23 (2002).
   Google Scholar
• Lal A, Glazer CA, Martinson HM et al. Mutant epidermal growth factor receptor upregulates molecular effectors of tumor invasion. Cancer Res. 62,3335–3339 (2002).
   PubMed Web of Science ®Google Scholar
• Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD 1839 ('Iressa') inhibits HER2- driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61,7184–7188 (2001).
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor related peptides and their receptors in human malignancies. Grit. Rev Oncol Hematol 19,183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long-term survival. Br. Cancer 68,162–165 (1993).
   Google Scholar
• Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur j Cancer 37(S4), 9–15 (2001).
   Google Scholar
• Rusnak D, Affleck K, Cockerill SG et al The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 61, 7196–7203 (2001).
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Nicholson RI, Gee JM. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin. Cancer Res. 7(S12), 4350–4355 (2001).
   Google Scholar
• Akimoto T, Hunter NR, Buchmiller L, Mason IKA, Ang KK, Milas L. Inverse relationship between epidermal growth factor expression and radiocurability of murine carcinomas. Clin. Cancer Res. 5, 2884–2890 (1999).
   PubMed Web of Science ®Google Scholar
• Wollman R, Yahalom J, Maxy R, Pinto J, Fucks Z. Effect of epidermal growth factor on the growth and radiation sensitivity of human breast cancer cell in vitro. Int. J. Racliat. Oiled Biol. Phys. 30,91–98 (1994).
   Google Scholar
• Sirotnak F, Zakowski M, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against tumor xenografts is markedly enhanced by coadministration of ZD-1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6,4885-4892 (2000).
   Google Scholar
• •Demonstrates the synergy between chemotherapy and EGFR-tyrosine kinase inhibitor, creating the premises for clinical trials with combined approach.
   Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94(5), 1593–1611 (2002).
   PubMed Web of Science ®Google Scholar
• Ciardello F, Caputo R, Bianco R et al Inhibition of growth factor production and angiogenesis in human cancer cells by ZD 1839 (Iressa), a selective epidermal growth factor inhibitor. Clin. Cancer Res. 7, 1459–65 (2001).
   Google Scholar
• Yang XD, Jia XC, Corvalan JRF, Wang P, Davis CG. Development of ABX-EGF, a fully human antiEGF receptor monoclonal antibody, for cancer therapy. Grit. Rev awl Hematol 38, 17–23 (2001).
   Google Scholar
• Moyer JD, Barbacci EG, Iwata KK et al Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57(21), 4838–4848 (1997).
   Google Scholar
• •First publication reporting preclinical activity of erlotinib (OSI-774, formerly CP 358,774).
   Google Scholar
• Karp DD, Ferrante KJ, Tensfeld TG et al A Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor CP-358,774 in patients with advanced solid tumors. Lung Cancer 29(S1), 65 (2000).
   Google Scholar
• Hidalgo M, Malik S, Rowinsky E et al Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc. Am. Soc. Clin. Oncol USA (2001) (Abstract 281).
   Google Scholar
• Rowinsky EK, Hammond L, Siu L et al Dose-schedule-finding, pharmacokinetic (PK), biologic and functional imaging studies of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor. Proc. Am. Soc. Clin. Oncol USA (2001) (Abstract 5).
   Google Scholar
• Busse D, Doughty RS, Ramsey TT et al Reversible G1 arrest induced by inhibition of the epidermal growth factor tyrosine kinase requires upregulation of p27 kipl independent of MAPK activity. J. Biol. Chem. 275, 6987–6995 (2000).
   Google Scholar
• Perez-Soler R, Chachoua A, Huberman M et al A Phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFR-expressing, non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. awl USA (2001) (Abstract 1235).
   Google Scholar
• Baselga J. Why the epidermal growth factor receptor? The rationale for therapy. Oncologist 7 (S4), 2–8 (2002) .
   PubMedGoogle Scholar
• Iwata KK, Provoncha K, Gibson N. Inhibition of mutant EGFRvIII transformed cells by tyrosine kinase inhibitor OSI-774 (Tarceva). Proc. Am. Soc. Clin. Oncol USA (2002) (Abstract 79).
   Google Scholar
• Rogers LR, Kadin W, Nadler P, Shields AF, LoRusso P. Response of cerebella hemangioblastomas associated with von Hippel-Lindau disease to OSI-774 (TarcevaTm). Proc. Am Soc. Clin. Oncol USA (2002) (Abstract 2111).
   Google Scholar
• Rojo F, Albanell J, Del Campo M et al Activation of mitogen-activated protein kinase (MAPK) is associated with epidermal growth factor receptor (EGFR), transforming growth factor (TGF-a) and HER2 receptor overexpression in head and neck tumors. Proc. Am. Soc. Clin. Oncol USA (2000) (Abstract 2417).
   Google Scholar
• Kahlenberg MS, Talamantez J, DeBonno J, Brattain MG. Receptor tyrosine kinase compensation in response to epidermal growth factor receptor inhibition. Proc. Am. Assoc. Cancer Res. 1116 (2003) (Abstract 4868).
   Google Scholar
• Elsayed YA, Sausville EA. Selected novel anticancer treatments targeting cell signaling proteins. Oncologist 6(6), 517–537 (2001).
   Google Scholar
• Naruse I, Ohmori T, Ao Y et al Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD 1839) in an EGFR-expressing multi-drug resistant cell line in vitro and in vivo. Int.j Cancer98, 310–315 (2002).
   Google Scholar
• Karp DD, Silberman SL, Csudae R et al Phase I dose escalation study of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774 in patients with advanced solid tumors. Proc. Am. Soc. Clin. 0=1 USA (1999) (Abstract).
   Google Scholar
• Hidalgo M, Siu LL, Nemunaitis J et al Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. Clin. Oncol 19(13), 3267–3279 (2001).
   Google Scholar
• Siu LL, Hidalgo M, Nemunitis J et al Dose and schedule-duration escalation of the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor CP-358,774: a Phase I and pharmacokinetics study. Proc. Am. Soc. Clin. Oncol USA (1999) (Abstract 1498).
   Google Scholar
• Finkler N, Gordon A, Crozier M et al Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Clin. Oncol USA (2001) (Abstract 831).
   Google Scholar
• Senzer NN, Soulieres D, Siu L et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Clin. Oncol USA (2001) (Abstract 6).
   Google Scholar
• Frassoldati A, Adami F, Banzi C et al. Changes of biological features in breast cancer cells determined by the primary chemotherapy. Breast Cancer Res. 7i-eat. 44, 185–192 (1997).
   Google Scholar
• Ng SS, Tsao MS, Nicldee T, Hedley D. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signalling pathways and apoptosis in human pancreatic adenocarcinoma. Mal Cancer Ther 1(10), 777–738 (2002).
   Google Scholar
• Ratain MJ, George CM, Janisch L et al. Phase I trial of erlotinib (OSI-774) in combination with gemcitabine (C) and cisplatin (P) in patients with advanced solid tumors. Proc. Am. Soc. Clin. awl USA (2002) (Abstract 2115).
   Google Scholar
• Forero L, Patnaik A, Hammond LA et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. Proc. Am. Soc. Clin. Oncol USA (2002) (Abstract 1908).
   Google Scholar
• Forouzesh B, Hidalgo M, Takimoto C et al Phase I, pharmacokinetic (PK) and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel Proc. Am. Soc. Clin. Oncol USA (2002) (Abstract 81).
   Google Scholar
• Albanell J, Rojo F, Averbuch S et al Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD 1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. Clin. Oncol 20(1), 110–124 (2002).
   Google Scholar
• Johnson DH, Herbst R, Giaccone G et al ZD1839 ('Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a Phase III clinical trial (INTACT 2). Ann. Oncol 13(S15), 127 (2002) (Abstract 468).
   Google Scholar
• Miller VA, Johnson D, Heelan RT et al. A pilot trial demonstrates the safety of oral ZD-1839 ('Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in combination with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Proc. Am. Soc. Gun. Oncol USA 19 (2001) (Abstract 1301).
   Google Scholar
• Lonardo F, Dragnev KH, Freemantle SJ et al Evidence for the epidermal growth factor receptor as target for lung cancer prevention. Clin. Cancer Res. 8,54–60 (2002).
   PubMed Web of Science ®Google Scholar
• Wakeling AE. Epidermal growth factor receptor tyrosine kinase inhibitors. C1.117: Opin. Pharmacol 2(4), 382–387 (2002).
   Google Scholar
• Huang SM, Armstrong E, Chinnaiyan P, Harari PM. Dual agent molecular targeting of the epidermal growth factor receptor: combining antiHERVEGFR monoclonal antibody with tyrosine kinase inhibitor. Proc. Am. Assoc. Cancer Res. 864 (2003) (Abstract 3777).
   Google Scholar
• Torrance CJ, Jackson PE, Montgomery E et al Combinatorial chemoprevention for intestinal neoplasia. Nature Merl 6, 1024–1028 (2000).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancers by ZD 1839 (Iressa), an epidermal growth factor receptor selective tyrosine kinase inhibitor. Clin. Cancer Res. 6,2053-2063 (2000).
   Google Scholar
• •Preclinical data supporting the use of EGFR tyrosine kinase inhibition and chemotherapy.
   Google Scholar